Posted: August 14, 2019 Shirish Gadgeel, MBBS, is the Mary Lou Kennedy Research Professor in Thoracic Oncology and a professor in the Division of Hematology/Oncology at the University of Michigan Rogel […] Read more

Posted: August 14, 2019 Mark A. Socinski, MD, executive medical director of AdventHealth Cancer Institute, spoke with the IASLC Lung Cancer News about his personal recommendations for TKI-refractory disease, especially for […] Read more

Posted: August 14, 2019 Lorlatinib, a smallmolecule inhibitor of ALK and ROS1, was granted accelerated U.S. Food and Drug Administration approval in November 2018 for patients with ALK-positive metastatic NSCLC whose […] Read more

By Christian Rolfo, MD, PhD, MBA, Dr.h.c., and Lori Alexander, MTPW, ELS, MWC Posted: August 14, 2019 Targeted therapy has become the standard of care in patients with advanced NSCLC and […] Read more

By Emily F. Collier, MD; Roy S. Herbst, MD, PhD; and Sarah B. Goldberg, MD, MPH Posted: August 14, 2019 Dr. Emily F. Collier Dr. Roy S. Herbst Dr. Sarah B. […] Read more

Posted: August 14, 2019 People diagnosed with lung cancer do not have to live close to a major cancer center to get a second opinion from one of its experts, thanks […] Read more

Posted: May 27, 2019 ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a large umbrella trial evaluating patients with early-stage NSCLC who have undergone complete tumor resection. As […] Read more

By Paul A. Bunn Jr., MD Posted: May 27, 2019 It is indeed an exciting time in lung cancer therapeutics, and we have reasons to be optimistic. To put these advances […] Read more

By Cornedine Jannette de Gooijer, MD; Maria Disselhorst, MD; and Paul Baas, MD, PhD Posted: May 27, 2019 Dr. Cornedine Jannette de Gooijer Until 2015, few changes occurred with respect to […] Read more

Posted: May 27, 2019 In March 2019, another successful Best of the World Lung Cancer Conference (BWLCC) was held in Lima, Peru. This was the fourth year in a row that […] Read more